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Cardiovascular disease (CVD) is a well-known complication of diabetes mellitus (DM), and
patients with DM are at an increased risk for early onset of CVD. Hyperglycemia is believed
to be the primary mediator in premature development of atherosclerosis in patients with
DM, but there are also derangements in cholesterol levels and inﬂammatory markers
beyond the explanation of hyperglycemia. Although clinicians often screen for dyslipidemia
as part of routine care for children and adolescents with DM, many do not feel comfort-
able treating this condition. Multiple guidelines exist to help clinicians with the prevention,
screening, and treatment of CVD risk factors in pediatric patients with DM, but the guide-
lines do not always agree on screening intervals or medical treatment. Furthermore, the
cost-effectiveness of medication use in this population has not been established. Research
has advanced our understanding of the role of other biomarkers and radiologic studies of
CVD risk, but these studies do not currently have a place in routine clinical practice. It is
evident that the increased CVD risk in pediatric patients with DM is complex in origin and
the optimal approach to managing dyslipidemia remains unclear. Therefore, an algorithm
designed at the University of North Carolina (UNC), Division of Pediatric Endocrinology,
is presented to help guide clinicians through screening and treatment of dyslipidemia in
youth with DM.
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INTRODUCTION
Cardiovascular disease (CVD) is a well-known complication of
diabetes mellitus (DM), and patients with DM are at an increased
risk for early onset of CVD. It is evident that atherosclerosis begins
in childhood (Berenson et al., 1992; Strong et al., 1999); how-
ever, CVD risk factors are most frequently assessed in the adult
population.A cross-sectional analysis of theGerman diabetes doc-
umentation and quality management system (DPV) showed that
of the 33,488 pediatric patients with type 1 diabetes (T1D) in
the system between September 2007 and September 2008, only
26% had no additional risk factors for CVD [Hemoglobin A1c
(HbA1c) ≥7.5%, hypertension, dyslipidemia, obesity, and smok-
ing], 39% had one risk factor, and 35% had two or more (Schwab
et al., 2010)!
Studies have shown that adults with T1D diagnosed in child-
hood developmore advanced atherosclerosis earlier in life than the
general population (Valsania et al., 1991) and have a higher rate
of cardiac failure (Savage and Semple, 2010) and shorter survival
(Portuese and Orchard, 1995). The primary mediator in ather-
osclerosis for patients with T1D is hyperglycemia (Kavey et al.,
2006). Optimizing glycemic control in patients with DM is gener-
ally accepted as the foundation for improving CVD risk; however,
the approach to dyslipidemia treatment in the setting of optimal
glycemic control is less clear.
With the rise in obesity, insulin resistance, and type 2 dia-
betes (T2D) in youth, increasing evidence suggests that these
patients may be at an even greater risk for CVD than similar
aged adolescents with T1D (Wadwa, 2006). Insulin resistance
contributes to dyslipidemia as both hepatic synthesis of very-
low-density lipoprotein (VLDL-C) is enhanced and peripheral
action of lipoprotein lipase is decreased, leading to increases
in low-density lipoprotein (LDL-C) and triglyceride (TG) levels
(Kavey et al., 2006; Savage and Semple, 2010). These derange-
ments as well as low HDL-C levels have been shown to corre-
late with the degree of atherosclerosis in children (NCEP Expert
Panel on Blood Cholesterol Levels in Children and Adolescents,
1992).
Much research has been done to identify biomarkers and non-
invasive radiological ﬁndings that suggest either existing CVD
or CVD risk. While measurements such as carotid intima media
thickness (cIMT) and C-reactive protein (CRP) are used as mark-
ers of CVD in adults, their utility in pediatrics is debatable. Beyond
the use of these studies in the research ﬁeld, their role in pediatric
clinical practice has not been established.
CURRENT CHOLESTEROL GUIDELINES
Many guidelines have been developed to help clinicians man-
age patients with DM and dyslipidemia (see Table 1). In this
age of evidence-based medicine, it is disappointing that the rec-
ommendations must be frequently based on individual expert
opinions and clinical experience. Researchers have had difﬁculty
obtaining prospective longitudinal data and experimenting with
drugs and interventions in children, thereby limiting the evidence
available.
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Table 1 | Cholesterol guidelines overview*.
NCEP Expert Panel on
Blood Cholesterol Lev-
els in Children, (1992)
AAP, (2008)
†
ADA (2003, 2005,
‡
2010, 2011)
ISPAD, (2009)§ AHA, (2006)||
Initial
screen type
1 diabetes
Not addressed Not addressed Patients >2 years age with positive
or unknown family history: soon
after diagnosis after establishing
glycemic control.
If negative family history: puberty or
10 years age (2011, 2010).
Patients >2 years age with
positive or unknown family
history: soon after
diagnosis after establishing
glycemic control.
If negative family history:
12 years age.
Not addressed
Screening
interval
type 1
diabetes
Not addressed Not addressed If normal, every 5 years (2011, 2010);
if abnormal, yearly (2011). If treated
with pharmacotherapy, repeat FLP
in 3 and 6months then annually
(2003).
If normal, every 5 years. Not addressed
Initial
screen type
2 diabetes
Not addressed Not addressed After establishing glycemic control
(2010, 2011).
Not addressed Not addressed
Screening
interval
type 2
diabetes
Not addressed Not addressed If normal, every 5 years; if abnormal,
yearly (2010, 2011). If normal, every
2 years (2003). If treated with
pharmacotherapy, repeat FLP in 3
and 6months then annually (2003).
Not addressed Not addressed
Target LDL-C <110mg/dL LDL-C
<130mg/dL
LDL-C <100mg/dL (2010, 2011),
HDL-C >35mg/dL, TG <150mg/dL
(2003).
Not addressed LDL-C ≤100 for T1D
and high-riskT2D. LDL-
C ≤130 in low riskT2D.
Recom-
mended
therapy
Step-one
diet×3months. If not
at target, proceed to
Step-two diet. If not at
target, consider medical
therapy.
Step-two diet.
If not at target,
consider phar-
macotherapy if
>10 years age.
If LDL-C elevated, optimize glycemic
control and initiate Step-two diet. If
LDL-C is not lower than 160 or
130mg/dL in patients with
additional risk, then initiate statin
(2010, 2011) at the lowest dose and
titrate as needed to achieve target.
If TG elevated, optimize glucose
control, weight loss if needed, and
ﬁbric acid medication if TG
>1,000mg/dL (2003).
Not addressed Step-two diet and
avoid trans fats×
6months. If not at
target, consider statin
use if ≥10 years age.
Adverse
effect
monitoring
Not addressed Not addressed LFTs, symptoms of muscle pain
(2003), risk of statin use in
pregnancy (2005).
Symptoms of muscle pain Not addressed
*Guidelines are listed in the order of which they were discussed in the text. The order does not indicate author preference. †Daniels et al. (2008). ‡ Silverstein et al.
(2005). §Donaghue et al. (2009). ||Kavey et al. (2006).
In 1992, the National Cholesterol Education Program (NCEP)
published guidelines for approaching dyslipidemia in children;
however, dyslipidemia management speciﬁcally in patients with
DM is not addressed. These guidelines describe a two-step dietary
approach for elevated LDL-C treatment prior to medical ther-
apy. Step-one of this approach entails a low fat diet (≤30% of
total calories from total fat, <10% of total calories from satu-
rated fatty acids, ≤ of total calories from polyunsaturated fatty
acids), <300mg/day of cholesterol, carbohydrates accounting
for 55% of total calories, and protein accounting for 15–20%
of total calories. Patients should practice this step-one diet for
3months. If the patients do not achieve target LDL-C levels of
<110mg/dL, then patients should proceed to the step-two diet,
in which saturated fatty acids now comprise <7% of total calo-
ries and cholesterol is limited to <200mg/day (NCEP Expert
Panel on Blood Cholesterol Levels in Children and Adolescents,
1992).
The Dietary Intervention Study in Children demonstrated that
after 3 years of follow-up, there was a signiﬁcant difference in
LDL-C levels after implementing a step-two diet compared to the
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usual care group with no adverse effects on growth and devel-
opment (Kwiterovich, 2001). If LDL-C levels are not at target
after practicing step-two of the dietary changes, thenmedical ther-
apy should be considered in children aged ≥10 years with LDL-C
≥190mg/dL or LDL-C >160mg/dL with either a positive family
history of CVD before age 55 years or presence of ≥2 risk fac-
tors (cigaret smoking, hypertension, HDL-C <35mg/dL, body
mass index (BMI) ≥95% percentile, DM, and physical inactiv-
ity; NCEP Expert Panel on Blood Cholesterol Levels in Children
andAdolescents, 1992). The 2008AmericanAcademy of Pediatrics
guidelines entitled “Lipid Screening and Cardiovascular Health in
Childhood” recommended consideration of pharmacotherapy in
patients with DM and LDL-C ≥130mg/dL if ≥10 years of age or
older (Daniels et al., 2008).
According to the 2010 and 2011 American Diabetes Associa-
tion (ADA)“Standards of Medical Care in Diabetes,”patients with
T1D who are>2 years of age with a family history of hypercholes-
terolemia [total cholesterol (TC) >240mg/dL], a cardiovascular
event before age 55 years, or unknown family history should be
screened with a fasting lipid proﬁle (FLP) soon after diagnosis and
glycemic control has been achieved. If family history is not con-
cerning, then lipid screening should begin at puberty or ≥10 years
of age. If DM diagnosis occurs after puberty, then a FLP should
be performed after establishing glycemic control. If LDL-C levels
are <100mg/dL, then the lipid proﬁle should be repeated every
5 years (American Diabetes Association, 2010, 2011). According
to the 2011 guidelines, if the proﬁle is abnormal, it should be
repeated yearly (American Diabetes Association, 2011). However,
it is not clear if this screening interval is different for patients
treated with cholesterol-lowering medications. In patients with
T2D, FLP should be obtained at the time of diagnosis. After diag-
nosis of T2D, bothADA standards state that guidelines are“similar
to those for youth with type 1 diabetes,” suggesting that screen-
ing occur after establishing glycemic control then every 5 years if
LDL-C is <100mg/dL or every 1 year if LDL-C is >100mg/dL
(American Diabetes Association, 2010, 2011). These 2010 and
2011 standards differ somewhat from the ADA’s 2003 consen-
sus statement on “Management of Dyslipidemia in Children and
Adolescents with Diabetes.” Previously, the recommended screen-
ing interval in patients with T2D with normal lipid proﬁles was
every 2 years (AmericanDiabetesAssociation,2003).With thehigh
prevalence of comorbidities in patientswithT2Dand the insidious
nature of symptom–onset leading to possibly years prior to diag-
nosis, it seems that the more frequent monitoring of lipid proﬁles
would be favored.
For patients diagnosed with dyslipidemia from FLPs, the ini-
tial recommended therapy according to the 2010 and 2011 ADA
guidelines should include optimizing glycemic control and using
step-two of the NCEP diet as described above. After 10 years of
age, if lifestyle changes have not lowered the LDL-C to ≤160
or ≤130mg/dL in patients with additional CVD risk factors,
then a statin is recommended for therapy to achieve a LDL-C
of<100mg/dL (American Diabetes Association, 2010, 2011). The
ADA recommended that statins should be started at the lowest
dose available and titrated up as needed. Periodic monitoring of
liver function tests (LFTs) is necessary in statin use, and medica-
tions should be stopped if LFTs exceed three times the upper limit
of normal. Statins should also be discontinued if persistentmuscle
pain occurs,but routine creatinine phosphokinasemonitoringwas
not felt to be helpful (American Diabetes Association, 2003).
Though the Lovastatin in Adolescent Male study has shown
statins to decrease LDL-C levels without adverse effects on growth
and development in adolescent males over 7 years when compared
to usual care, the ADA has recognized that long-term safety and
efﬁcacy data is not available (Kwiterovich, 2001; American Dia-
betes Association, 2010, 2011). In the 2005 guidelines entitled
“Care of Children and Adolescents with Type 1 Diabetes” the ADA
also raised concerns about the use of statins in sexually active
females as these drugs are not approved in pregnant individuals
(Silverstein et al., 2005).
The 2003 statement further describes optimal HDL-C levels of
>35mg/dL and TG levels<150mg/dL. Elevated TG levels should
be treated by optimizing glucose control, weight loss if needed,
and using ﬁbric acid medication if TG levels ≥1,000mg/dL. For
patients on medical treatment for dyslipidemia, the ADA recom-
mends repeating a FLP 3 and 6months after therapy initiation,
and then annually once treatment goals are achieved (American
Diabetes Association, 2003).
The International Society for Pediatric andAdolescentDiabetes
published clinical practice guidelines in 2009 similar to the ADA
guidelines from 2010 to 2011 with the exception that initial lipid
screening in patients without a family history of CVD andwithout
additional risk factors should begin at age 12 years. The recom-
mended interventions for dyslipidemia included improvement of
glycemic control and statin use. The authors also recognized that
long-term safety of statins has not yet been established (Donaghue
et al., 2009).
In the 2006 scientiﬁc statement regarding CVD risk reduction
in high-risk pediatric patients, the American Heart Association
(AHA) identiﬁed T1D and T2D as one of eight conditions at risk
for premature atherosclerosis beginning in childhood. The evi-
dence for early coronary disease further stratiﬁed T1D as part of
the high-risk tier I category and T2D as part of the moderate risk
tier II category. However, patients with T2D are usually classiﬁed
as high risk in tier I because of the presence of at least two other
comorbidities (dyslipidemia, smoking, CVD ≤55 years of age for
ﬁrst degree male relatives and ≤65 years of age for ﬁrst degree
female relatives, hypertension, overweight/obese, physically inac-
tive). Children within tier I should be approached as having a
“coronary heart disease equivalent.” The AHA recommends that
those patients in the tier 1 category obtain LDL-C≤ 100mg/dL
and those within the tier II category obtain LDL-C≤ 130mg/dL.
In order to reach these cholesterol levels, the ﬁrst recommended
step is to initiate the NCEP step-two diet under the guidance of
a nutritionist with the addition of avoidance of trans fats for
6months. If LDL-C goals are not achieved, then statin therapy
should be considered if the child is older than 10 years of age
(Kavey et al., 2006). The AHA guidelines were endorsed by the
American Academy of Pediatrics.
Aside from the 2003 ADA consensus statement that addresses
hypertriglyceridemia, there are no other ofﬁcial guidelines for the
approach to TG or HDL-C management. The Pittsburgh Epi-
demiology of Diabetes Complications Study evaluated 10 years of
mortality andmorbidity data related toT1D. In this study of nearly
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600 patients, risk ratios were calculated between cholesterol lev-
els and mortality, coronary artery disease, and overt nephropathy.
Based on risk ratios of at least 1.8, the following cholesterol goal
levels were recommended by the researchers: LDL-C<100mg/dL,
HDL-C>45mg/dL, TG<150mg/dL (Orchard et al., 2001).
Recent studies have suggested that additional lipid parameters
may be useful in the assessment and management of youth with
DM. The SEARCH for Diabetes in Youth study found an associa-
tion between glycemic control and fasting lipid concentrations in
subjects with T1D, as those with a HbA1c <7.5% had similar TC
andLDL-C levels but lowerTGandhigherHDL-C levels compared
to healthy controls, while the patients with HbA1c≥7.5% had ele-
vated TC, LDL-C, non-HDL-C, and HDL-C levels. Interestingly,
the subjects with DM (even those in optimal control) had signif-
icantly higher apolipoprotein B (Apo B) and a greater number of
small dense LDL-C particles than the control subjects, suggesting
that the lipids in patients with DM in some ways may be more
atherogenic. Small dense LDL-C, which contains less cholesterol
per particle and tends to become oxidized, has been shown to be an
independent predictor of CVD (Guy et al., 2009). In patients with
DM, LDL-C particle number may be higher at any given LDL-C
concentration, likely because of the increased percentage of small
dense LDL-Cparticles (Vijayaraghavan,2010).ApoBhas also been
shown to be an independent predictor of CVD and may provide
a better estimate of LDL-C particle number than LDL-C or non-
HDL-C in patients with insulin resistance and DM (Ganda, 2009).
Therefore, it may be useful for future guidelines to incorporate
other lipid parameters as additional goals of therapy. Overall, it
appears that there are both gaps and discrepancies among the dif-
ferent clinical guidelines, making it difﬁcult for providers who are
seeking speciﬁc guidelines for their patients with DM.
COST OF DYSLIPIDEMIA
The incidence rates of both T1D and T2D are rising, and with
them the burden of their complications. As with much other data
in pediatric DM, cost-analysis data does not exist for the treat-
ment of dyslipidemia beginning in childhood. Adult literature
shows that several European cost-effectiveness studies based on
the “Collaborative Atorvastatin Diabetes Study” have determined
atorvastatin use in adults to be cost–effective to various degrees
depending on the country in which the drug is to be used when
compared to no treatment in the prevention of CVD (Raikou et al.,
2007; Lafuma et al., 2008; Annemans et al., 2010).
A systematic review of interventions in adults for prevent-
ing and controlling DM demonstrated that statin use was “very
cost–effective” in the secondary prevention of CVD, while those
strategies described as “cost–effective” included the primary pre-
vention of CVD for patients with T2D and hyperlipidemia, inten-
sive insulin treatment for people with T1D compared with con-
ventional glycemic control, and intensive glycemic control by a
Diabetes Prevention Program type of intensive lifestyle interven-
tion (ILI) in people with newly diagnosed T2D compared with
conventional glycemic control. Surprisingly, intensive glycemic
control for all U.S. residents with T2D diagnosed at age ≥25 years
compared with usual care was only “marginally cost–effective”
(Li et al., 2010). One would presume that glycemic control
would be the most cost–effective since it is considered to be the
cornerstone of dyslipidemia treatment. The AHEAD study exam-
ined the cost-savings of an ILI regimen compared to aDM support
and education system in adults with T2D. In this study, the ILI
group improved their lipid proﬁles, decreased medication use,
and saved $40 per month in medication costs (Redmon et al.,
2010).
OTHER CVD RISK MARKERS
Other biomarkers and radiologic testing are frequently performed
for research purposes to better understand the pathophysiological
course of CVD, but what is the role of this testing in routine clin-
ical practice? Before implementing these tests into routine care,
normative values must be established in the healthy pediatric
population for each of these tests.
Carotid intimamedia thickness has been used in the adult pop-
ulation to assess the degree of CVDrisk due to atherosclerosis. This
practice is based on studies suggesting that cIMT correlates with
risk of cardiovascular events (deGroot et al., 2004).One longitudi-
nal study of patients with T1D over a 2-year period showed that of
the patients who had an elevated cIMT at baseline, those who had
worsening of cIMT also had a higher HbA1c, though there were
no signiﬁcant differences in lipid proﬁle, systolic blood pressure,
or BMI measurements (Dalla Pozza et al., 2010). Although studies
have also revealed a thicker cIMT in patients with T1D compared
to those without DM, conﬂicting data exists regarding whether
cIMT is associated with DM duration (Atabek et al., 2006; Dalla
Pozza et al., 2007; Rabago Rodriguez et al., 2007; Margeirsdottir
et al., 2010).
One study from the International Childhood Cardiovascular
Cohort (iC3) Consortium examined the association in healthy
subjects between cholesterol, BMI, and systolic blood pressure
among different childhood age groups and cIMT in adulthood.
This study showed that TC level was associatedwith cIMT in adult-
hood beginning at age 12, systolic blood pressure was associated
with cIMT beginning at age 6, and BMI was associated with cIMT
beginning at age 9 (Juonala et al., 2006,2010).A similar study using
data from theBogalusaHeart Study,YoungFinns Study, andChild-
hood Determinants of Adult Health Study found that adolescents
with elevated LDL-C had an increased risk of high cIMT if LDL-C
did not normalize by adulthood. Both groups with persistent low
HDL-Candwith lowHDL-C that normalized by adulthoodhad an
increased risk of high cIMT (Magnussen et al., 2009). While these
CVD risk factors in children predict cIMT in adulthood, what
does cIMT in childhood indicate? Furthermore, to what extent are
cIMT derangements found in childhood reversible through early
interventions?
Many studies have examined the normative values for cIMT
in healthy children. Some studies suggest that cIMT is positively
associated with age (Ishizu et al., 2004; Bohm et al., 2009), while
other studies do not ﬁnd this association (Sass et al., 1998). Gen-
der differences were appreciated in onemajor study by Bohm et al.
(2009), but not found in another large study in a similar popula-
tion (Jourdan et al., 2005). Clearly there is disagreement in cIMT
measurements even in similar populations and none of the stan-
dards proposed would be generalizable to a clinic with patients
of mixed ethnic and racial backgrounds. It is also likely that cIMT
methods vary across institutions andmay be evaluator-dependent.
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Other radiologic measures for assessing vascular function
include arterial compliance, stiffness, and distensibility. Two stud-
ies (one adult, one pediatric) have shown that patients with T1D
have lower arterial compliance and distensibility when compared
to healthy controls; nevertheless, exercise was shown to improve
thesemeasures in both groups, but not to the same levels as healthy
controls (Mason et al., 2006; Trigona et al., 2010). Although some
evidence suggests that patients with T1D have reduced arterial
compliance and distensibility as well as increased arterial stiffness,
some studies disagree (Galler et al., 2010; Margeirsdottir et al.,
2010). A scientiﬁc statement by the AHA in 2009 regarding the
use of measurements of cIMT, coronary artery calciﬁcation by
computed tomography, arterial stiffness, arterial distensibility, and
arterial dilation concluded that “Additional data are needed before
thesemethods can be adopted in clinical evaluation”(Urbina et al.,
2009).
Many researchers focus on the role of inﬂammation in CVD
development. Pediatric patientswithT1Dhavebeen shown tohave
increased inﬂammatory markers even with acceptable glycemic
control (Snell-Bergeon et al., 2010). In two studies of children and
young adults with T1D, elevated serum levels of inﬂammatory
markers such as CRP were associated with higher cIMT measure-
ments, suggesting an increased risk of CVD(Hayaishi-Okano et al.,
2002; Atabek et al., 2006). However, another study showed that
while CRP in childhood was weakly associated with CRP levels in
adulthood, it was not associated with cIMT in adulthood (Juonala
et al., 2006). It is important to note that standard CRP norma-
tive ranges are generally not reported in the pediatric population
(McNeal et al., 2009).
A recent study showed that inﬂammatory markers such as IL-6
and ﬁbrinogenwere elevated in youthwith T1D, regardless of their
weight status or glycemic control. High sensitivity CRP (hs-CRP)
was also found tobehigher in the patientswithworsening glycemic
control. Moreover, elevations in these inﬂammatory markers were
associated with a more atherogenic lipid proﬁle (higher TC, LDL-
C, and Apo B, but lower HDL-C; Snell-Bergeon et al., 2010).
Other biomarkers that reﬂect endothelial cell dysfunction have
been studied very little in children. One study found that patients
with T1D had elevated levels of intercellular adhesion molecule
(ICAM), nitric oxide (NO), and malondialdehyde (MDA) when
compared to healthy controls, and those with poor glycemic con-
trol also had higher levels of vascular endothelial growth factor
(VEGF; Seckin et al., 2006).
One routine measurement that is used to screen for nephropa-
thy may have a new role in predicting CVD risk: urine microalbu-
min. Adult studies have shown 24 h urine albumin levels to predict
increased risk for CVD in both patients with T1D and T2D (Deck-
ert et al., 1996; Miettinen et al., 1996; Zhan et al., 2009). While it
is exciting to think of the possibility of using one tool to screen
for two common complications of DM, little is known about the
predictive value of microalbuminuria for CVD in the pediatric
population.
CHOLESTEROL ALGORITHM
At the UNC, Division of Pediatric Endocrinology, we have com-
piled the major guidelines and consensus statements regarding
dyslipidemia management in pediatric patients with DM into an
algorithm designed to help our providers practically apply the
latest recommendations regarding lipid screening and treatment
(see Figure 1). We are in the process of collecting data to evalu-
ate its effectiveness. The algorithm underwent review by the UNC
Pediatric Endocrinology Division members prior to implementa-
tion and has been approved by the Division for use in the UNC
Pediatric Endocrinology diabetes clinic.
Of note, our screening interval for patients with T2D who have
a history of normal lipids is based on the ADA’s guidelines from
2003, because we felt that their high prevalence of comorbidities
and increased risk for CVD warrants closer monitoring of lipids.
Our initial screen is a non-FLP (TC, HDL-C, and non-HDL-C)
because most of our patients do not come to appointments fast-
ing. If our patients have been fasting for more than 8 h, we begin
with a FLP (TC,LDL,TG,HDL-C).We rely on theUNC laboratory
reference range for distinguishing normal from abnormal values
for non-FLPs. These ranges may differ at other institutions. We
rescreen patients with normal non-FLPs the same as the 2003ADA
recommended screening intervals for patients with normal FLPs.
If the non-FLP is abnormal,we then arrange a FLP for further eval-
uation. Our algorithm is then based on the 2011 ADA guidelines
unless a different set of guidelines addresses a topic not addressed
by the 2011ADA guidelines. Because there has been little guidance
besides lifestyle modiﬁcations in the approach to improving low
HDL-C or elevated TG levels, we have not addressed these choles-
terol derangements in our algorithm. Our diabetes care providers
have felt that this tool has been a useful reference for when to
screen for and how to treat dyslipidemia in the UNC pediatric
diabetes population.
CONCLUSION
Cholesterol screening is not universal among pediatricians, and
despite compelling data that pediatric patients with DM are at
increased risk for CVD, clinicians often do not feel comfort-
able prescribing dyslipidemicmedications because of concerns for
long-termmedication safety. Additionally, there is no longitudinal
data to show that early dyslipidemia treatment improves CVDout-
come. One prescription claims data study of commercially insured
children in the United States from 2004 to 2007 showed that the
prevalence of dyslipidemia medication prescriptions was 0.2 per
1000 youths, of which statins accounted for 56.9%. During the
study period, dyslipidemia prescription claims dropped by 14–
20% overall except in 16–18 year old females whose use increased
by 14%; however, insurance claims for statins decreased by 22.9%
overall (Liberman et al., 2009).
Current clinical guidelines addressing dyslipidemia in youth
with DM have been derived from expert opinions or extrapo-
lated from the adult literature. There are limited recommendations
regarding treatment of high TG or low HDL-C, and the most
current guidelines do not clearly delineate any differences in the
approach to pediatric T1Dversus T2D. Because recent studies have
revealed a greater number of CVD risk factors in youth with T2D
compared to those with T1D, guidelines for pediatric T2D may
need to be more aggressive.
Further studies are needed to evaluate the long-term safety and
effectiveness of statins and other cholesterol-loweringmedications
in children with DM, and to determine whether early treatment
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FIGURE 1 | University of North Carolina-Chapel Hill pediatric endocrinology cholesterol algorithm.
signiﬁcantly reducesCVD in adulthood.Additional research is also
needed to explore the clinical usefulness of various biomarkers
and radiographic measurements. Though the optimal approach
to managing dyslipidemia in pediatric patients with DM remains
unclear, it can be conﬁdently stated that they are at high risk for
CVD, andwe, as themedical and scientiﬁc community,must strive
to ﬁnd the optimal prevention, screening, and treatment regimen.
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